

DAFTAR PUSTAKA

- Albini, Adriana, Francesca Tosetti, Vincent W. Li, Douglas M. Noonan, and William W. Li. 2012. Cancer Prevention by Targeting Angiogenesis. *Nature Reviews. Clinical Oncology*, **9**: 498–509.
- Anand, P., Kunnumakkara, A.B., Newman, R.A., dan Aggarwal, B.B., 2007. Bioavailability of Curcumin: Problems and Promises. *Molecular Pharmaceutics*, **4**: 807–818.
- Araújo, C. C., and L. L. Leon. 2001. Biological Activities of Curcuma Longa L. *Memorias Do Instituto Oswaldo Cruz*, **96**: 723–28.
- ATCC, 2016. <https://atcc.org/Products/All/CCL-81.aspx> characteristics, 31 Agustus 2018.
- Bauer, Katrina R., Monica Brown, Rosemary D. Cress, Carol A. Parise, and Vincent Caggiano. 2007. Descriptive Analysis of Estrogen Receptor (ER)-Negative, Progesterone Receptor (PR)-Negative, and HER2-Negative Invasive Breast Cancer, the so-Called Triple-Negative Phenotype. *Cancer*, **109**: 1721–28.
- Bausero, M.A., Bharti, A., Page, D.T., Perez, K.D., Eng, J.W.-L., Ordonez, S.L., dkk., 2006. Silencing the *hsp25* Gene Eliminates Migration Capability of the Highly Metastatic Murine 4T1 Breast Adenocarcinoma Cell. *Tumor Biology*, **27**: 17–26.
- Castle-Miller, Jennifer, David O. Bates, and Domingo J. Tortones. 2017. Mechanisms Regulating Angiogenesis Underlie Seasonal Control of Pituitary Function. *Proceedings of the National Academy of Sciences*, **114**: E2514–23.
- Corbett, T.H., Griswold, D.P., Roberts, B.J., Peckham, J.C., dan Schabel, F.M., 1975. Tumor Induction Relationships in Development of Transplantable Cancers of the Colon in Mice for Chemotherapy Assays, with a Note on Carcinogen Structure. *Cancer Research*, **35**: 2434–2439.
- Costa, R.L.B., Han, H.S., dan Gradishar, W.J., 2018. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. *Breast Cancer Research and Treatment*, **169**: 397–406.
- Cristofanilli, M., and G. N. Hortobagyi. 2002. Molecular Targets in Breast Cancer: Current Status and Future Directions. *Endocrine-Related Cancer*, **9**: 249–66.

- Da'i M., Supardjan A.M., Meiyanto E., Jenie U.A. and Kawaichi M., 2007. Potensi Antiproliferative Analog Kurkumin Pentagamavunon Terhadap Sel Kanker Payudara T47D. *Artocarpus*, **7**: 14–20.
- Da'i, M., 2003. Uji Aktivitas Antiproliferatif Pentagamavunon-0 terhadap Sel Raji, Sel HeLa dan Sel Myeloma. Tesis, Program Pascasarjana UGM, Yogyakarta.
- Da'i, M., Meiyanto, E. dan Supardjan, A.M., 2004. Efek antiproliferatif Pentagamvunon-0 terhadap sel myeloma. *Sains Kesehatan Majalah Berkala Penelitian Pascasarjana Ilmu-ilmu Kesehatan Universitas Gajah Mada*, **17** (1): 1-11.
- Dent, Rebecca, Wedad M. Hanna, Maureen Trudeau, Ellen Rawlinson, Ping Sun, and Steven A. Narod. 2009. Pattern of Metastatic Spread in Triple-Negative Breast Cancer. *Breast Cancer Research and Treatment*, **115**: 423–28.
- Diaz, Leslie K., Vincent L. Cryns, W. Fraser Symmans, and Nour Sneige. 2007. Triple Negative Breast Carcinoma and the Basal Phenotype: From Expression Profiling to Clinical Practice. *Advances in Anatomic Pathology*, **14**: 419–30.
- Dolinsky, C. & Hill-Kayser, C., 2013. Breast Cancer: The Basics Oncolink Cancer Resources. <http://www.oncolink.org>, 31 Agustus 2018.
- Foulkes, W.D., Smith, I.E., dan Reis-Filho, J.S., 2010. Triple-negative breast cancer. *The New England Journal of Medicine*, **363**: 1938–1948.
- Gadi, Vijayakrishna K., and Nancy E. Davidson. 2017. Practical Approach to Triple-Negative Breast Cancer. *Journal of Oncology Practice*, **13**: 293–300.
- Greenberg, Sally, and Hope S. Rugo. 2010. Triple-Negative Breast Cancer: Role of Antiangiogenic Agents. *Cancer Journal (Sudbury, Mass.)*, **16**: 33–38.
- Grothey, A. dan Ellis, L.M., 2008. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. *Cancer Journal (Sudbury, Mass.)*, **14**: 170–177.
- Hermawan, A., Fitriasari, A., Junedi, S., Ikawati, M., Haryanti, S., Widaryanti, B., dkk., 2011. PGV-0 AND PGV-1 INCREASED APOPTOSIS INDUCTION OF DOXORUBICIN ON MCF-7 BREAST CANCER CELLS **12**: 55–59.
- Hicklin, D.J. dan Ellis, L.M., 2005. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *Journal of Clinical Oncology*:

Official Journal of the American Society of Clinical Oncology, **23**: 1011–1027.

- Jiao, D., Wang, J., Lu, W., Tang, X., Chen, J., Mou, H., dkk., 2016. Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer. *Molecular Therapy - Oncolytics*, **3**: 16018.
- Jin, Xin, and Ping Mu. 2015. Targeting Breast Cancer Metastasis. *Breast Cancer: Basic and Clinical Research*, **9**: 23–34.
- Kumar, P., Bolshette, N.B., Jamdade, V.S., Mundhe, N.A., Thakur, K.K., Saikia, K.K., dkk., 2013. Breast cancer status in India: An overview. *Biomedicine & Preventive Nutrition*, **3**: 177–183.
- Kunnumakkara, Ajaikumar B., Preetha Anand, and Bharat B. Aggarwal. 2008. Curcumin Inhibits Proliferation, Invasion, Angiogenesis and Metastasis of Different Cancers through Interaction with Multiple Cell Signaling Proteins. *Cancer Letters*, **269**: 199–225.
- Langseth, L., 1995, Oxidant, Antioxidant, and Disease Prevention, International Life Science Institute press, Belgium.
- Linderholm, B.K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtiö, J., dkk., 2009. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. *Annals of Oncology*, **20**: 1639–1646.
- Liu, D. dan Chen, Z., 2013. The effect of curcumin on breast cancer cells. *Journal of Breast Cancer*, **16**: 133–137.
- Liu, Dongwu, and Zhiwei Chen. “The Effect of Curcumin on Breast Cancer Cells. 2013. *Journal of Breast Cancer*, **16**: 133–37.
- Majeed, M., Badmaev, V., Shirakumar U. & Rajendran, R., 1995. Curcuminoids Antioxidant Phytonutrients, 3-80, NutriScience Publisher Inc., PisCataway, New Jersey.
- Matsumura, A., Kubota, T., Taiyoh, H., Fujiwara, H., Okamoto, K., Ichikawa, D., dkk., 2013. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. *International Journal of Oncology*, **42**: 535–542.
- Meiyanto, E., Agustina, D., A.M., Supardjan & Da’i, M., 2007. PGV-0 Apoptosis on T47D Breast Cancer Line Through Caspase-3 Activation. *Jurnal Kedokteran Yarsi*, **15** (2): 75-79.

- Meiyanto, E., M. Rosinta., dan Da'i M. 2006. PGV-1 menurunkan ekspresi faktor angiogenesis (VEGF dan COX-2) pada sel T47D terinduksi estrogen. *Majalah Farmasi Indonesia*, **17** (1): 1 – 6.
- Meiyanto, E., Putri, D.D.P., Susidarti, R.A., Murwanti, R., Sardjiman, S., Fitriasari, A., dkk., 2014. Curcumin and its Analogues (PGV-0 and PGV-1) Enhance Sensitivity of Resistant MCF-7 Cells to Doxorubicin through Inhibition of HER2 and NF-kB Activation. *Asian Pacific Journal of Cancer Prevention*, **15**: 179–184.
- Miller, K.D., Sweeney, C.J., dan Sledge, G.W., 2001. Redefining the target: chemotherapeutics as antiangiogenics. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **19**: 1195–1206.
- Moos, Philip J., Kornelia Edes, James E. Mullally, and Frank A. Fitzpatrick. 2004. Curcumin Impairs Tumor Suppressor P53 Function in Colon Cancer Cells. *Carcinogenesis*, **25**: 1611–17.
- Nurrochmad, A., 2001. Sintesis kurkumin, bisdemetoksikurkumin, bisdemetoksihidroksikurkumin dan Pentagamavunon-0 serta uji kesitotoksikannya terhadap sel Mieloma dan sel Mononuklear normal secara in vitro. Tesis, Program Pascasarjana UGM, Yogyakarta.
- Oetari, R.A., Sardjiman, Yuwono, T. & Hakim, L., 2001. Upaya Peningkatan Absorpsi Senyawa Baru Antiinflamasi PGV-0. Laporan Penelitian Hibah Bersaing IX/1 Perguruan Tinggi, Lembaga Penelitian Universitas Gadjah Mada, 17.
- Orbayinah, S., Ismadi, M. & Oetari. 2003. Kemampuan Menghambat dan Sifat Hambatan Analog Kurkumin Terhadap Aktivitas Enzim Siklooksigenase. *Majalah Berkala Penelitian Pascasarjana Ilmu-ilmu Kesehatan Universitas Gajah Mada*, **6** (1): 29-39.
- Otvos, L., Kovalszky, I., Riolfi, M., Ferla, R., Olah, J., Sztodola, A., dkk., 2011. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. *European Journal of Cancer*, **47**: 1578–1584.
- Pan, Z., Zhuang, J., Ji, C., Cai, Z., Liao, W., dan Huang, Z., 2018. Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression. *Oncology Letters*, **15**: 4821–4826.
- Panno, Joseph. 2005. *Cancer: The Role of Genes, Lifestyle, and Environment*. Infobase Publishing, 2005.
- Robinson, Thomas Philip, Tedman Ehlers, Richard B. Hubbard IV, Xianhe Bai, Jack L. Arbiser, David J. Goldsmith, and J. Phillip Bowen. 2003. Design,

Synthesis, and Biological Evaluation of Angiogenesis Inhibitors: Aromatic Enone and Dienone Analogues of Curcumin. *Bioorganic & Medicinal Chemistry Letters*, **13**: 115–17.

Samanta, Debangshu, Youngrok Park, Xuhao Ni, Huili Li, Cynthia A. Zahnow, Edward Gabrielson, Fan Pan, and Gregg L. Semenza. 2018. Chemotherapy Induces Enrichment of CD47+/CD73+/PDL1+ Immune Evasive Triple-Negative Breast Cancer Cells. *Proceedings of the National Academy of Sciences*, **115**: E1239–48.

Saraswat, D., Nehra, S., Chaudhary, K.K., dan Prasad, C.V.S.S., 2014. In-silico screening and in-vitro validation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) inhibitors. *Bioinformatics*, **10**: 273–280.

Scappaticci, F.A., 2002. Mechanisms and future directions for angiogenesis-based cancer therapies. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **20**: 3906–3927.

Septisetyani, S.P., Ikawati, M., Widaryanti, B. & Meiyanto, E., 2008. Apoptosis Mediated Cytotoxicity of Curcumin Analogues PGV-0 and PGV-1 in WiDr Cell Line. *Proceeding Molecular Targeted Therapy Symposium 2008*, 48-56.

Shan, B., Schaaf, C., Schmidt, A., Lucia, K., Buchfelder, M., Losa, M., dkk., 2012. Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas. *Journal of Endocrinology*, **214**: 389–398.

Shishodia, S., Sethi, G. & Aggarwal, B.B., 2005. Curcumin: Getting Back to the Roots. *Ann. N.Y.Acad.Sci.*, **1056**: 206-217.

Singh, P. dan Bast, F., 2014. Multitargeted molecular docking study of plant-derived natural products on phosphoinositide-3 kinase pathway components. *Medicinal Chemistry Research*, **23**: 1690–1700.

Singh, R.K., Rai, D., Yadav, D., Bhargava, A., Balzarini, J., dan De Clercq, E., 2010. Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid. *European Journal of Medicinal Chemistry*, **45**: 1078–1086.

Tao, Kai, Min Fang, Joseph Alroy, and G. Gary Sahagian. 2008. Imagable 4T1 Model for the Study of Late Stage Breast Cancer. *BMC Cancer*, **8**: 228.

Tim Molnas Fak. Farmasi UGM. 2001. Uji Antiinflamasi Senyawa PGV-0, PGV-1, dan HGV-1 Pada Tikus Jantan dan Betina dan Elusidasi Mekanisme Antiinflamasi. Laporan Penelitian Tim Molnas, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta.

- Torre, Lindsey A., Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, dan Ahmedin Jemal. 2012. Global Cancer Statistics, 2012: Global Cancer Statistics. *CA: A Cancer Journal for Clinicians*, **65**: 87–108.
- Wahba, Hanan Ahmed, and Hend Ahmed El-Hadaad. 2015. Current Approaches in Treatment of Triple-Negative Breast Cancer. *Cancer Biology & Medicine*, **12**: 106–16.
- Yan, Chunhong, and Douglas D. Boyd. 2007. Regulation of Matrix Metalloproteinase Gene Expression. *Journal of Cellular Physiology*, **211**: 19–26.
- Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J., dan Holash, J., 2000. Vascular-specific growth factors and blood vessel formation. *Nature*, **407**: 242–248.
- Yu, S., Shen, G., Khor, T.O., Kim, J.-H., dan Kong, A.-N.T., 2008. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. *Molecular Cancer Therapeutics*, **7**: 2609–2620.